GlassScriptPhysician profile
Catherine B Silver
NPI 1033589122
$1,081.07
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $477 · 2024: $604.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,011 · Education: $69.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,011.08 |
| Education | $69.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $131.10 | 2023-2024 | Reblozyl, Pomalyst |
| Lilly USA, LLC | $117.70 | 2023-2024 | Jaypirca, Verzenio, Retevmo |
| Seagen INC. | $112.51 | 2023 | Tukysa, Padcev |
| Takeda Pharmaceuticals U.S.A., INC. | $63.83 | 2023-2024 | Hyqvia |
| Pfizer INC. | $53.21 | 2024 | |
| Janssen Biotech, INC. | $50.37 | 2024 | Erleada, Talvey, Darzalex |
| Ipsen Biopharmaceuticals, INC | $49.78 | 2024 | Onivyde, Somatuline Depot |
| Incyte Corporation | $48.66 | 2023 | Pemazyre, Monjuvi |
| Shield Therapeutics INC | $48.46 | 2023 | Accrufer |
| Aveo Pharmaceuticals, INC. | $43.44 | 2023 | Fotivda |
| Genzyme Corporation | $42.44 | 2024 | |
| Alnylam Pharmaceuticals INC. | $34.79 | 2024 | Givlaari |
| Adaptive Biotechnologies Corporation | $30.52 | 2024 | Clonoseq |
| Mirati Therapeutics, INC. | $29.86 | 2024 | Krazati |
| Daiichi Sankyo INC. | $26.78 | 2023 | Injectafer |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $26.08 | 2024 | Keytruda, Welireg |
| Gilead Sciences, INC. | $24.74 | 2023 | |
| Glaxosmithkline, LLC. | $23.93 | 2023 | Shingrix |
| Astrazeneca Pharmaceuticals LP | $21.17 | 2024 | Wainua |
| Array Biopharma INC | $21.09 | 2024 | Braftovi, Lorbrena |
| Alexion Pharmaceuticals, INC. | $20.77 | 2024 | Ultomiris |
| Kyowa Kirin, INC. | $20.36 | 2023 | Poteligeo |
| Novartis Pharmaceuticals Corporation | $20.08 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $19.40 | 2024 | Opdualag |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Catherine Silver listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.